MedTrace Logo

Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators

NCT01952379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-11-25

No results posted yet for this study

Summary

Melasma is an acquired hyperpigmentary disorder that commonly affects women from Asia and Latin-America.There is evidence of subclinical inflammation supported by diffuse spectrometry and by prominent inflammatory cells in affected areas; however this infiltrate and its inflammatory mediators remains unexplored. Chronic inflammation induces melanogenesis and angiogenesis; thus, it could be linked to its recurrent nature.Therefore, the aim of this study is to describe the inflammatory cellular infiltrate, and the expression of main inflammatory and angiogenic mediators in this condition, as well as to explore its relationship with severity of disease.

Using histological, histochemistry, immunohistochemistry, and quantitative real-time PCR, we evaluated melasma lesions from 20 healthy female patients with malar melasma without specific solar exposure or photoprotection measures within the previous 3 weeks and compared them to non lesional skin.

Conditions

  • Melasma

Sponsors & Collaborators

  • Hospital Central "Dr. Ignacio Morones Prieto"

    collaborator OTHER

  • Universidad Autonoma de San Luis Potosí

    lead OTHER

Principal Investigators

  • Juan P Castanedo-Cazares, MD · Hospital Central "Dr. Ignacio Morones Prieto"

  • Bertha Torres-Alvarez, MD · Hospital Central "Dr. Ignacio Morones Prieto"

  • Adriana Rodriguez-Arambula, MD · Hospital Central "Dr. Ignacio Morones Prieto"

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01952379 on ClinicalTrials.gov